1. Home
  2. WEYS vs CTNM Comparison

WEYS vs CTNM Comparison

Compare WEYS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weyco Group Inc.

WEYS

Weyco Group Inc.

HOLD

Current Price

$34.18

Market Cap

280.9M

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$11.80

Market Cap

416.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEYS
CTNM
Founded
1906
2009
Country
United States
United States
Employees
N/A
41
Industry
Apparel
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
280.9M
416.1M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
WEYS
CTNM
Price
$34.18
$11.80
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.00
AVG Volume (30 Days)
17.0K
294.3K
Earning Date
11-04-2025
10-30-2025
Dividend Yield
3.16%
N/A
EPS Growth
N/A
N/A
EPS
2.54
N/A
Revenue
$279,843,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.51
$3.35
52 Week High
$38.24
$15.25

Technical Indicators

Market Signals
Indicator
WEYS
CTNM
Relative Strength Index (RSI) 56.89 52.45
Support Level $33.48 $11.50
Resistance Level $34.44 $12.00
Average True Range (ATR) 1.10 0.66
MACD 0.20 -0.03
Stochastic Oscillator 69.18 41.78

Price Performance

Historical Comparison
WEYS
CTNM

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: